Interferon-beta in patients with low-grade astrocytomas--a phase I study

Area of Science:

• Neuro-oncology
• Pharmacology
• Immunology

Background:

• Low-grade astrocytomas are primary brain tumors.
• Interferon-beta is a cytokine with potential anti-tumor activity.
• Understanding the clinical pharmacology of interferon-beta is crucial for its therapeutic application.

Purpose of the Study:

• To investigate the clinical pharmacology of interferon-beta in patients with low-grade astrocytomas.
• To assess the dose-dependent plasma levels and pharmacokinetic profile of interferon-beta.
• To evaluate the safety, tolerability, and biological activity of interferon-beta in this patient population.

Main Methods:

• A Phase I clinical study involving 3 patients with low-grade astrocytomas.
• Administration of escalating doses of interferon-beta (2.3 to 69 X 10^6 U/patient) via weekly infusions.
• Monitoring of plasma interferon-beta levels, pharmacokinetic parameters, hematological changes, and Natural Killer cell activity.

Main Results:

• Dose-dependent plasma levels of interferon-beta up to 5800 IU/ml were achieved.
• Biphasic decline in plasma concentrations with half-lives of T1 1/2: 0.095-0.49 hrs and T2 1/2: 5-14.5 hrs.
• Mild side effects (fatigue, myalgia, fever) and transient hematological changes (lymphopenia, granulocytosis) were observed. Natural Killer cell activity showed an initial drop followed by a significant increase.

Conclusions:

• Interferon-beta demonstrated high biological activity in the plasma of astrocytoma patients.
• The drug was well-tolerated with manageable toxicity in this Phase I study.
• Further investigation into interferon-beta as a potential therapeutic agent for low-grade astrocytomas is warranted.